UK Must Use Biosimilar Savings To Provide Earlier Access To Biologics
Executive Summary
The UK may be busy sweeping up the savings being generated with the rapid uptake of biosimilars, but more needs to be done to show how this money is being channelled back into the healthcare system to the benefit of patients.
You may also be interested in...
Humira Under Pressure As NHS England Invites 'Competitive Prices' For Biosimilars
Companies wanting to compete in the newly off-patent adalimumab market in England have until Oct. 22 to submit their bids. They will need to offer “competitive prices” if they are to secure the highest share of sales to the national health service. At the same time, NHS trusts and clinical commissioning groups have been warned not to accept discounted interim offers from suppliers keen to get a foot in the door.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.